Targeting cancer with antibody-drug conjugates: Promises and challenges

Antibody-drug conjugates (ADCs) are a rapidly expanding class of biotherapeutics that utilize antibodies to selectively deliver cytotoxic drugs to the tumor site. As of May 2021, the U.S. Food and Drug Administration (FDA) has approved ten ADCs, namely Adcetris®, Kadcyla®, Besponsa®, Mylotarg®, Poli...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Alexis Q. Dean, Shen Luo, Julianne D. Twomey, Baolin Zhang
Format: Artigo
Sprache:Inglês
Veröffentlicht: Taylor & Francis Group 2021-01-01
Schriftenreihe:mAbs
Schlagworte:
Antibody–drug conjugate (adc)
monoclonal antibody (mAb)
cytotoxic payload
bioconjugation
cancer therapy
analytics
Online Zugang:https://www.tandfonline.com/doi/10.1080/19420862.2021.1951427
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge